Clinical Trials Logo

Clinical Trial Summary

When treating very short children in puberty we are time-limited, as sex hormones cause the growth plates to fuse and growth to end. Growth Hormone (GH), plus drugs that stop puberty, increase height potential, but leave children sexually infantile at a critical time in development. Human and animal data show that estrogen, in females and males, is a principal regulator of the fusion of the growth plate in puberty. Using aromatase inhibitors (AIs), which block testosterone to estrogen conversion, in boys with different growth disorders, we have shown that AIs may have beneficial effects enhancing height potential in growth-retarded males, without affecting their puberty. However, no direct comparison of the effect of AIs alone vs. conventional GH treatment has been done to date. This study will assess the effect of AIs alone, GH alone and combination treatment in enhancing height potential in adolescent boys with idiopathic short stature.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01248416
Study type Interventional
Source Nemours Children's Clinic
Contact
Status Completed
Phase Phase 3
Start date November 2010
Completion date September 2016

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06382155 - A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature Phase 2
Recruiting NCT05894876 - A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
Completed NCT01246219 - Short Stature Related Distress Phase 4
Completed NCT00965484 - Genotropin Study Assessing Use of Injection Pen Phase 3
Completed NCT00710307 - Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)
Completed NCT01504802 - Pharmacodynamics of CNP During Growth Hormone Treatment N/A
Completed NCT00488124 - Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin Phase 2
Withdrawn NCT01438801 - Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF) Phase 4
Recruiting NCT06309979 - A Study to Assess Growth in Children With Idiopathic Short Stature
Terminated NCT00121875 - Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature Phase 4
Not yet recruiting NCT05858606 - Multidisciplinary Evaluation and a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients N/A
Active, not recruiting NCT04020913 - Skeletal Muscle Effects of GH in Boys
Completed NCT01401244 - Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers Phase 1
Recruiting NCT02973061 - The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents
Completed NCT01778023 - Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature Phase 3
Recruiting NCT01604395 - Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
Active, not recruiting NCT00840944 - A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height Phase 4
Completed NCT01070173 - Ghrelin Levels in Children With Poor Growth N/A
Completed NCT01543867 - Safety and Efficacy of Long-term Somatropin Treatment in Children N/A
Recruiting NCT04798690 - Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature